Author: Li, Si; Sharma, Nishant; Kazmierski, Daniel; Amjad, Mohammad Asim; Dong, Yishan; Wang, Yichen; Sharma, Namita; Ramakrishna, Srinivasarao; Ochieng, Pius
Title: Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy Cord-id: ufr316wy Document date: 2021_6_21
ID: ufr316wy
Snippet: Immune checkpoint blockade is a rapidly expanding therapeutic modality in oncology. However, its adverse effects extend beyond the cytotoxicity of conventional chemotherapy. Pneumotoxicity associated with immune checkpoint therapy presents a diagnostic conundrum that has been further complicated by the COVID-19 pandemic. We report a case of a patient with metastatic urothelial carcinoma who developed diffuse alveolar hemorrhage (DAH) following treatment with avelumab.
Document: Immune checkpoint blockade is a rapidly expanding therapeutic modality in oncology. However, its adverse effects extend beyond the cytotoxicity of conventional chemotherapy. Pneumotoxicity associated with immune checkpoint therapy presents a diagnostic conundrum that has been further complicated by the COVID-19 pandemic. We report a case of a patient with metastatic urothelial carcinoma who developed diffuse alveolar hemorrhage (DAH) following treatment with avelumab.
Search related documents:
Co phrase search for related documents- activity relationship and lung injury: 1
Co phrase search for related documents, hyperlinks ordered by date